Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

SWECARNET - Sweden´s CAR T-cell Competence Network

Reference number
Coordinator Karolinska Institutet - Karolinska Institutet Inst f laboratoriemedicin
Funding from Vinnova SEK 3 500 000
Project duration December 2022 - June 2026
Status Ongoing

Purpose and goal

SWECARNET is an open network of key representatives in the Swedish CAR T field from academia, healthcare, and industry working towards knowledge exchange and development of standardized processes for CAR T delivery and follow-up. SWECARNET’s central goal is to implement gene-modified immune effector cell therapy, such as CAR T, so that patients in need, and likely to benefit, get access to new treatments through clinical trials or as standard of care treatment independent of where they are living in the country.

Expected effects and result

The collaboration in this network will facilitate the translation of advanced therapies into clinical use and create an arena for innovation within academia and healthcare to be generated in, and with help from industry to reach patients. SWECARNET is expected to be at the forefront of the field both nationally and internationally and serve as a workhorse for solving challenges around the implementation of advanced therapies. SWECARNET will act as a catalyst to increase the number of clinical trials for CAR T and other advanced therapy medicinal products in Sweden.

Planned approach and implementation

All members in SWECARNET will be involved and work together on 8 different work packages with an assigned project leader. SWECARNET arranges quarterly meetings where we work together, follow up and report the progress made in the various work packages. SWECARNET is led by Professor Stephan Mielke, Karolinska Institutet and Karolinska Universitetssjukhuset together with Professor Gunilla Enblad, Uppsala Universitet and Akademiska Sjukhuset.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 5 December 2022

Reference number 2022-03107